Skip to content
Biodatica
Start free

Lantern Pharma Inc.

Beverly Hills, California

OncologyPhase IIListed · LTRN

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Phase II trial registered: A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma

2mo agoTrial registeredMay 4, 2026Source filing (opens the source filing in a new tab)

Momentum

85no change

Momentum 85 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase II

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE1/PHASE2 registered

    Jun 9, 2023

    Advanced Solid Tumor, Metastatic Solid Tumor, GBM, TNBC - Triple-Negative Breast Cancer, NSCLC, Pancreatic Adenocarcinoma, DDR Gene Mutation · ACTIVE_NOT_RECRUITING · sponsor: Lantern Pharma Inc. · Study of LP-184 in Patients With Advanced Solid Tumors

    ClinicalTrials.gov · NCT05933265 (opens the source filing in a new tab)

  2. Trial

    PHASE2 registered

    Mar 1, 2023

    Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung · RECRUITING · sponsor: Lantern Pharma Inc. · A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma

    ClinicalTrials.gov · NCT05456256 (opens the source filing in a new tab)

  3. Trial

    PHASE1 registered

    Jan 3, 2023

    Relapsed or Refractory Lymphomas, Advanced Solid Tumor · RECRUITING · sponsor: Lantern Pharma Inc. · Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors

    ClinicalTrials.gov · NCT06132503 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources